0000000000855695

AUTHOR

Lucie Bouquet

showing 2 related works from this author

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma

2021

We evaluated the safety and immunogenicity of the BNT162b2 vaccine in 52 patients with multiple myeloma (MM). Median age was 71.3 (range, 39.6-90.8) years. 26 (50%) patients had received active treatment including an immunomodulatory drug (IMiD) (n=21), an anti-CD38 monoclonal antibody (n=11) and/or a proteasome inhibitor (n=4). 21 had received previous treatment interrupted at a median of 27.5 (range, 3.5-169.3) months before first vaccine inoculum. 5 patients had indolent untreated MM. 35 patients had a history of autologous hematopoietic cell transplantation (HSCT) performed at a median of 44.4 (range, 3.5-169.3) months before first vaccine inoculum. The vaccination was well tolerated wi…

Cancer Researchmedicine.medical_specialtybiologybusiness.industryImmunogenicityELISPOTHematologymedicine.diseaseGastroenterologyPoster PresentationsVaccinationTransplantationOncologyInternal medicinemedicinebiology.proteinSeroconversionAntibodybusinessAdverse effectMultiple myelomaClinical Lymphoma Myeloma and Leukemia
researchProduct

IL-1RAP, un candidat pour l’immunothérapie par CAR T-cells

2019

International audience; No abstract available

Regulation of gene expression0303 health sciencesMyeloidTransgenemedicine.medical_treatment[SDV]Life Sciences [q-bio]General MedicineImmunotherapyBiologymedicine.diseaseFusion proteinGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMyelogenousLeukemia0302 clinical medicinemedicine.anatomical_structureAntigen030220 oncology & carcinogenesismedicineCancer researchComputingMilieux_MISCELLANEOUS030304 developmental biology
researchProduct